AAPL325.13+8.28 (+2.61%) ▲|ABBV259.99+3.57 (+1.39%) ▲|ABT108.93-1.43 (-1.30%) ▼|ACN188.09-1.67 (-0.88%) ▼|ADBE286.08-6.71 (-2.29%) ▼|AMAT441.85-16.54 (-3.61%) ▼|AMD459.61-11.11 (-2.36%) ▼|AMGN438.12+8.24 (+1.92%) ▲|AMT176.02+0.32 (+0.18%) ▲|AMZN254.92-4.85 (-1.87%) ▼|AVGO369.68-0.66 (-0.18%) ▼|AXP324.19-5.98 (-1.81%) ▼|BA205.66-2.12 (-1.02%) ▼|BAC61.99+0.05 (+0.08%) ▲|BKNG195.69-3.40 (-1.71%) ▼|BLK1,128.10-27.51 (-2.38%) ▼|BMY66.92+0.11 (+0.16%) ▲|BNY160.51-0.77 (-0.48%) ▼|BRK-B502.33-1.70 (-0.34%) ▼|C132.54+0.92 (+0.70%) ▲|CAT779.16-18.31 (-2.30%) ▼|CL89.63-0.19 (-0.21%) ▼|CMCSA26.30-0.32 (-1.20%) ▼|COF211.34-3.17 (-1.48%) ▼|COP136.19+3.70 (+2.79%) ▲|COST939.96-3.93 (-0.42%) ▼|CRM258.11+0.57 (+0.22%) ▲|CSCO109.74-0.75 (-0.68%) ▼|CVS97.60+3.69 (+3.93%) ▲|CVX211.05+4.91 (+2.38%) ▲|DE676.08+21.17 (+3.23%) ▲|DHR206.93-6.63 (-3.10%) ▼|DIS106.22-1.33 (-1.24%) ▼|DUK120.39+0.48 (+0.40%) ▲|EMR147.63-4.81 (-3.16%) ▼|FDX324.88-2.52 (-0.77%) ▼|GD369.41-1.94 (-0.52%) ▼|GE331.09-4.62 (-1.38%) ▼|GEV898.53+0.00 (+0.00%) ▲|GILD149.92+3.58 (+2.45%) ▲|GM85.63-0.69 (-0.80%) ▼|GOOG332.03-3.38 (-1.01%) ▼|GOOGL335.02-4.33 (-1.28%) ▼|GS1,002.56-18.34 (-1.80%) ▼|HD319.77-8.06 (-2.46%) ▼|HON209.98-3.55 (-1.66%) ▼|IBM231.40-2.47 (-1.06%) ▼|INTC88.97-0.54 (-0.60%) ▼|INTU344.93-14.37 (-4.00%) ▼|ISRG369.25-7.61 (-2.02%) ▼|JNJ271.19+5.34 (+2.01%) ▲|JPM354.95-1.07 (-0.30%) ▼|KO88.00-0.67 (-0.76%) ▼|LIN486.76-2.82 (-0.58%) ▼|LLY1,160.00+3.27 (+0.28%) ▲|LMT544.50-13.28 (-2.38%) ▼|LOW200.05-4.65 (-2.27%) ▼|LRCX290.20-11.29 (-3.74%) ▼|MA581.10-8.21 (-1.39%) ▼|MCD261.11-0.57 (-0.22%) ▼|MDLZ61.61-0.46 (-0.74%) ▼|MDT92.04+1.39 (+1.53%) ▲|META578.54+6.20 (+1.08%) ▲|MMM170.24-1.59 (-0.93%) ▼|MO69.57+1.09 (+1.59%) ▲|MRK149.86+2.10 (+1.42%) ▲|MS211.04-2.28 (-1.07%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU933.44-25.29 (-2.64%) ▼|NEE82.93+0.59 (+0.72%) ▲|NFLX80.81-0.24 (-0.30%) ▼|NKE38.12-0.53 (-1.37%) ▼|NOW142.90-5.09 (-3.44%) ▼|NVDA217.44-3.06 (-1.39%) ▼|ORCL141.32-7.80 (-5.23%) ▼|PEP139.79-0.55 (-0.39%) ▼|PFE28.55+0.09 (+0.32%) ▲|PG146.21+1.09 (+0.75%) ▲|PLTR179.92-6.46 (-3.47%) ▼|PM187.15-0.15 (-0.08%) ▼|QCOM166.61-3.87 (-2.27%) ▼|RTX205.16-2.57 (-1.24%) ▼|SBUX106.15-0.10 (-0.09%) ▼|SCHW108.28-1.54 (-1.40%) ▼|SO88.09+0.09 (+0.10%) ▲|SPG211.87-0.45 (-0.21%) ▼|T26.00+0.11 (+0.42%) ▲|TMO600.50-16.60 (-2.69%) ▼|TMUS182.16+1.72 (+0.95%) ▲|TSLA356.09-11.86 (-3.22%) ▼|TXN253.34-7.57 (-2.90%) ▼|UBER75.24-0.41 (-0.54%) ▼|UNH396.30+6.89 (+1.77%) ▲|UNP290.62-10.05 (-3.34%) ▼|UPS102.66-1.57 (-1.51%) ▼|USB61.21-0.37 (-0.60%) ▼|V372.67-6.70 (-1.77%) ▼|VZ50.30+0.28 (+0.56%) ▲|WFC87.04+0.65 (+0.75%) ▲|WMT105.92+1.05 (+1.00%) ▲|XOM164.55+3.60 (+2.24%) ▲|AAPL325.13+8.28 (+2.61%) ▲|ABBV259.99+3.57 (+1.39%) ▲|ABT108.93-1.43 (-1.30%) ▼|ACN188.09-1.67 (-0.88%) ▼|ADBE286.08-6.71 (-2.29%) ▼|AMAT441.85-16.54 (-3.61%) ▼|AMD459.61-11.11 (-2.36%) ▼|AMGN438.12+8.24 (+1.92%) ▲|AMT176.02+0.32 (+0.18%) ▲|AMZN254.92-4.85 (-1.87%) ▼|AVGO369.68-0.66 (-0.18%) ▼|AXP324.19-5.98 (-1.81%) ▼|BA205.66-2.12 (-1.02%) ▼|BAC61.99+0.05 (+0.08%) ▲|BKNG195.69-3.40 (-1.71%) ▼|BLK1,128.10-27.51 (-2.38%) ▼|BMY66.92+0.11 (+0.16%) ▲|BNY160.51-0.77 (-0.48%) ▼|BRK-B502.33-1.70 (-0.34%) ▼|C132.54+0.92 (+0.70%) ▲|CAT779.16-18.31 (-2.30%) ▼|CL89.63-0.19 (-0.21%) ▼|CMCSA26.30-0.32 (-1.20%) ▼|COF211.34-3.17 (-1.48%) ▼|COP136.19+3.70 (+2.79%) ▲|COST939.96-3.93 (-0.42%) ▼|CRM258.11+0.57 (+0.22%) ▲|CSCO109.74-0.75 (-0.68%) ▼|CVS97.60+3.69 (+3.93%) ▲|CVX211.05+4.91 (+2.38%) ▲|DE676.08+21.17 (+3.23%) ▲|DHR206.93-6.63 (-3.10%) ▼|DIS106.22-1.33 (-1.24%) ▼|DUK120.39+0.48 (+0.40%) ▲|EMR147.63-4.81 (-3.16%) ▼|FDX324.88-2.52 (-0.77%) ▼|GD369.41-1.94 (-0.52%) ▼|GE331.09-4.62 (-1.38%) ▼|GEV898.53+0.00 (+0.00%) ▲|GILD149.92+3.58 (+2.45%) ▲|GM85.63-0.69 (-0.80%) ▼|GOOG332.03-3.38 (-1.01%) ▼|GOOGL335.02-4.33 (-1.28%) ▼|GS1,002.56-18.34 (-1.80%) ▼|HD319.77-8.06 (-2.46%) ▼|HON209.98-3.55 (-1.66%) ▼|IBM231.40-2.47 (-1.06%) ▼|INTC88.97-0.54 (-0.60%) ▼|INTU344.93-14.37 (-4.00%) ▼|ISRG369.25-7.61 (-2.02%) ▼|JNJ271.19+5.34 (+2.01%) ▲|JPM354.95-1.07 (-0.30%) ▼|KO88.00-0.67 (-0.76%) ▼|LIN486.76-2.82 (-0.58%) ▼|LLY1,160.00+3.27 (+0.28%) ▲|LMT544.50-13.28 (-2.38%) ▼|LOW200.05-4.65 (-2.27%) ▼|LRCX290.20-11.29 (-3.74%) ▼|MA581.10-8.21 (-1.39%) ▼|MCD261.11-0.57 (-0.22%) ▼|MDLZ61.61-0.46 (-0.74%) ▼|MDT92.04+1.39 (+1.53%) ▲|META578.54+6.20 (+1.08%) ▲|MMM170.24-1.59 (-0.93%) ▼|MO69.57+1.09 (+1.59%) ▲|MRK149.86+2.10 (+1.42%) ▲|MS211.04-2.28 (-1.07%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU933.44-25.29 (-2.64%) ▼|NEE82.93+0.59 (+0.72%) ▲|NFLX80.81-0.24 (-0.30%) ▼|NKE38.12-0.53 (-1.37%) ▼|NOW142.90-5.09 (-3.44%) ▼|NVDA217.44-3.06 (-1.39%) ▼|ORCL141.32-7.80 (-5.23%) ▼|PEP139.79-0.55 (-0.39%) ▼|PFE28.55+0.09 (+0.32%) ▲|PG146.21+1.09 (+0.75%) ▲|PLTR179.92-6.46 (-3.47%) ▼|PM187.15-0.15 (-0.08%) ▼|QCOM166.61-3.87 (-2.27%) ▼|RTX205.16-2.57 (-1.24%) ▼|SBUX106.15-0.10 (-0.09%) ▼|SCHW108.28-1.54 (-1.40%) ▼|SO88.09+0.09 (+0.10%) ▲|SPG211.87-0.45 (-0.21%) ▼|T26.00+0.11 (+0.42%) ▲|TMO600.50-16.60 (-2.69%) ▼|TMUS182.16+1.72 (+0.95%) ▲|TSLA356.09-11.86 (-3.22%) ▼|TXN253.34-7.57 (-2.90%) ▼|UBER75.24-0.41 (-0.54%) ▼|UNH396.30+6.89 (+1.77%) ▲|UNP290.62-10.05 (-3.34%) ▼|UPS102.66-1.57 (-1.51%) ▼|USB61.21-0.37 (-0.60%) ▼|V372.67-6.70 (-1.77%) ▼|VZ50.30+0.28 (+0.56%) ▲|WFC87.04+0.65 (+0.75%) ▲|WMT105.92+1.05 (+1.00%) ▲|XOM164.55+3.60 (+2.24%) ▲|
20.7 C
New York
Wednesday, September 2, 2026

Tag: symptoms

newssourceFORcompanyinformationcontent1releasesmarket

Neuronetics Reports Second Quarter 2025 Financial and Operating Results

Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers.

Sciaticyl’s “Nerve Reset” Discovery Sparks 2025 Surge in Sciatica Support Solutions Across U.S.

A powerful surge in online searches for natural sciatica remedies has thrust Sciaticyl into the spotlight, thanks to a peculiar “nerve reset” approach linked to ancient herbal wisdom and modern neuroscience. This unique formulation blends 11 ingredients—including Bacopa Monnieri, Alpha Lipoic Acid, and key nerve-regenerating compounds—positioning Sciaticyl as a leading curiosity point for those seeking non-surgical options. As nerve pain awareness grows in 2025, researchers and consumers alike are exploring how nutritional support may play a role in long-term sciatica recovery, vitality, and freedom from discomfort. 
A powerful surge in online searches for natural sciatica remedies has thrust Sciaticyl into the spotlight, thanks to a peculiar “nerve reset” approach linked to ancient herbal wisdom and modern neuroscience. This unique formulation blends 11 ingredients—including Bacopa Monnieri, Alpha Lipoic Acid, and key nerve-regenerating compounds—positioning Sciaticyl as a leading curiosity point for those seeking non-surgical options. As nerve pain awareness grows in 2025, researchers and consumers alike are exploring how nutritional support may play a role in long-term sciatica recovery, vitality, and freedom from discomfort.

Why XentaFlex Is Emerging as 2025’s Most Affordable, Simplest, and Most Effective Joint Pain Solution

More Americans Are Rethinking Collagen, Glucosamine, and Pills in 2025 as Public Curiosity Shifts Toward Ingredient-First Joint Hydration Formulas Like Simple Promises' XentaFlex 
More Americans Are Rethinking Collagen, Glucosamine, and Pills in 2025 as Public Curiosity Shifts Toward Ingredient-First Joint Hydration Formulas Like Simple Promises' XentaFlex

Black Girl Vitamins Launches “Calm Girl”: A Stress-Relieving Ashwagandha Supplement Designed for Black Women’s Wellness

Chicago, IL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Black Girl Vitamins Launches “Calm Girl”: A Stress-Relieving Ashwagandha Supplement Designed for Black Women’s Wellness

Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight

The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...

Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight

The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...

How Women Can Tame Medication Costs for the Whole Family

MISSION, Kan., Aug. 4, 2025 /PRNewswire/ -- (Family Features) If you're the one tracking medications, scheduling appointments and making sure the whole household stays...

Freya Pharma Solutions Announces Launch of Phase II Clinical Dose-Response Study testing its LybridoTM Concept Targeting Female Sexual Dysfunction

www.freyapharmasolutions.com

MDLifespan and Dr. Jill Carnahan Launch “Next Gen Mold Detox” Using Therapeutic Plasma Exchange

Dr Jill's MDLifespan Mold Protocol is the First Clinically Proven Therapeutic Plasma Exchange Detox to Remove up to 90% of Mold Toxins DENVER, Aug. 4,...

The Hidden Lung Infection Impacting Millions: World NTM Day Puts Spotlight on Awareness

With Annual NTM Case Rates Rising, Patients and Providers Are Urged to Recognize the Symptoms and Risks MIAMI, Aug. 4, 2025 /PRNewswire/ -- As the...

AXA Launches “AXA Health Concierge” Delivering a One-Stop Health Management Solution Across Hong Kong and Mainland China

First-ever cross-border Green Medical Pass Integrating resources from both regions for efficient access to healthcare services HONG KONG, Aug. 4, 2025 /PRNewswire/ -- AXA Hong...

Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease

BEIJING, Aug. 3, 2025 /PRNewswire/ -- Raytone Biotech, a clinical-stage biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient...

First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR

SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSymptoms

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers